Ad
related to: what does azacitidine do- Dosing With INQOVI
Oral Dosing Schedule & What To Do
If Modifications Are Needed.
- Patient Considerations
Learn Which Patients May
Be Appropriate For INQOVI.
- Watch A Panel Discussion
See Medical Professionals & A
Patient Advocate Discuss INQOVI.
- Why INQOVI?
Learn How INQOVI May Help Your
Patients. Access Prescribing Info.
- INQOVI HCP Resources
Download Helpful Resources For
HCPs Treating With INQOVI.
- INQOVI Efficacy & Safety
Learn About Trial Results
Including Safety & Efficacy.
- Dosing With INQOVI
Search results
Results From The WOW.Com Content Network
Azacitidine is a chemical analogue of the nucleoside cytidine, which is present in DNA and RNA.It is thought to have antineoplastic activity via two mechanisms – at low doses, by inhibiting of DNA methyltransferase, causing hypomethylation of DNA, [16] and at high doses, by its direct cytotoxicity to abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA ...
Azacitidine and decitabine are marketed as Vidaza and Dacogen respectively. Azacitidine is the first drug to be approved by FDA for treating MDS and has been given orphan drug status. [2] [3] Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. [4]
A hypomethylating agent (or demethylating agent [1]) is a drug that inhibits DNA methylation: the modification of DNA nucleotides by addition of a methyl group.Because DNA methylation affects cellular function through successive generations of cells without changing the underlying DNA sequence, treatment with a hypomethylating agent is considered a type of epigenetic therapy.
Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.
Decitabine is a hypomethylating agent. [7] [8] It hypomethylates DNA by inhibiting DNA methyltransferase.It functions in a similar manner to azacitidine, although decitabine can only be incorporated into DNA strands while azacitidine can be incorporated into both DNA and RNA chains.
Obecabtagene autoleucel, sold under the brand name Aucatzyl, is an anti-cancer medication used for the treatment of acute lymphoblastic leukemia. [1] [2] It is a CD19-directed genetically modified autologous T-cell immunotherapy.
The drug methotrexate (bottom) is an antimetabolite that interferes with the metabolism of folic acid (top). An antimetabolite is a chemical that inhibits the use of a metabolite, which is another chemical that is part of normal metabolism. [1]
Decitabine/cedazuridine is indicated for treatment of adults with myelodysplastic syndromes, including previously treated and untreated, de novo and secondary myelodysplastic syndromes with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia) and intermediate-1 ...